Portfolio – Exits
MST – Medical Surgery Technology
MST is now the missing link between surgery and robotics. MST is an Image analyses system for the OR with 3 layers of products: Guided and robotic surgery; training platform; and big data AI analyses of the surgery image.
MST’s advanced image-based software empowers robotic surgery, enhancing performance and workflow efficiency to benefit patients, surgeons and healthcare providers. This is achieved by way of proprietary algorithmic architecture which provides intelligent scene cognition capabilities for autonomous powering of medical robots and computer-assisted surgery systems.
Exit: MST was sold in 2019 to TransEnterix in a cash and share swap deal executed through 2019 – 2021
Founded in 2012 in Korea, HEALCERION offers a mobile based healthcare system that is specifically designed to provide physicians and patients with point of care diagnostic information. The company is developing the world’s first Wireless Portable Ultrasound device.
Exit: Sale of shares 2017-1018
AngioLab, Inc. is Korean Biotechnology Company established in June 1999, developing pharmaceutical products based on angiogenesis inhibition to treat and/or prevent various angiogenesis-dependent diseases, such as cancers, ocular diseases, abdominal obesity, psoriasis and arthritis.
AngioLab focuses at this stage on 3 products: abdominal obesity; functional dietary supplement for abdominal obesity; functional cosmeceuticals and Wrinklestat.
Exit: Sale of shares 2018
Curaco is a nursing smart bidet for bedridden persons. To put it simply, it is a specially designed bidet for people with limited mobility such as the elderly, patients and ill.
The exclusive new technology provides revolutionary solution to home health care. When CURACO detects urine and/or faces with its advanced built-in sensors, it automatically flushes excrement away, rinses and dries the user’s body, ensuring cleanness and comfort for the user.
Exit: Sale of shares 2019
A bio-venture company, conducting R&D of diagnostic methods for degenerative brain diseases ever since its foundation in September 2002. It is currently focusing on the development of blood test for Alzheimer’s disease.
PeopleBio possesses a source technology to detect multimer proteins that induce the disease through simple blood test based on MDS (Multimer Detection System). Technology that detects biomarkers related to brain diseases such as Alzheimer’s disease can be utilized to effectively treat and prevent the diseases through early diagnosis and monitoring of progress.
Exit: Sale of shares 2018
A global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). Invested: 2009
Exit: February 2014: IPO on NASDAQ (cap $400m). May 2015 M&A by the Chinese XIO group (cap $517m).
Iscare B.V Medical Centers In the Czech Republic and Slovakia specializing in: assisted reproduction; complex treatment of obesity; gastroenterology and treatment of idiopathic intestinal inflammations and plastic surgery. Invested: 2008
Exit: January 2015: M&A by Private Equity fund.
Valeritas is a medical technology company committed to the development and commercialization of innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. The Valeritas medical technologies portfolio is headlined by the h-Patch™ technology. The V-Go Disposable Insulin Delivery Device, designed for the simple delivery of basal-bolus insulin therapy via a preset basal rate and on-demand bolus dosing around mealtimes, is the first use of the h-Patch™ technology.
Developed the fundamental technologies for peptide-based medicines. In line with proprietary technologies, company is developing sustained-release medications with a high technological entrance barrier and excellent product competitiveness, to treat life threatening and chronic diseases. Invested 2014.
Exit: January 2015: traded on Korea OTC market, July 2015: IPO on KOSDAQ at market cap of $236m.
The company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions. Invested 2012.
Exit: June 2015: IPO on NYSE, market cap $415m (GI).
BioInfra, Inc. is a Korean company established in 2001, developing a Multiplex Cancer Early Diagnostics service using In Vitro Diagnostics Multivariate Index Assay and Bioinformatics technology, specialized in detecting cancer and chronic disease through blood analysis. The company provides early cancer detection service based on over 7.2K validated cancer sample. BioInfra has created a diagnostic algorithm that uses bioinformatics, and have established 6 cancer score model.
Exit: February 2016, in OTC Market.
Portfolio under management
Sensimed AG, a Swiss company, has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish®, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.
The Company is now focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The 24-hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.
Epitomee medical is developing and commercializing drug-free self-administered, shapeshifting capsules, aimed to prevent diabetes and address overweight & obesity co-morbidities by promoting weight loss and establishing a healthier lifestyle. Epitomee have created a balance between ingestible devices and the body’s native mechanisms, to tackle some of today’s most prevalent chronic diseases at their core with a self-managed, safer, kinder to the system and more natural way.
BrainsGate is a developer of a novel therapeutic platform based on electrical neurostimulation of the Spheno-Palatine Ganglion (SPG). BrainsGate's leading indication is acute ischemic stroke with a 24-hour treatment window. Additional applications for the treatment of central nervous system disorders include Vascular Dementia and Drug Delivery to the CNS. BrainsGate is headquartered in Caesarea, Israel.
U2bio was Founded in Korea, and provides lab testing and IT services for clinics and hospitals based on a profound understanding of the hospital’s needs. U2Bio's main business is Lab & Molecular genetic testing, U2Bio also provides personalize healthcare service based on PHR & Genetic analysis.U2bio expands its business scope into Personal Healthcare domain based on individual health data gathered from lab testing service currently focusing on Human Milk Analysis (HMA) service.
Clew (Formerly: Intensix)
An analytics platform for the prediction of life threatening complications in high acuity care. Using high volume and high velocity analytics, Clew identifies patterns in physiological data that predict a deterioration in the patient’s condition, in real-time. The platform enables physicians to intervene in a timely manner, improving the clinical outcome and reducing the cost of treatment. www.clewmed.com
Dia Image Analysis
DiA is developing the next generation in how medical imaging will be analyzed, by providing fully automated supporting tools that enable quick, objective and accurate medical image interpretations.
Cognitive Image Processing Technology – DiA’s patented technology uses advanced pattern recognition and machine learning algorithms to automatically imitate the way the human eye identifies borders and motion. The algorithms produce quick, accurate and automated data and scoring for diagnosis.
DiA’s flagship, FDA/CE cleared toolbox delivers automatic and accurate evaluations of important indicators of the heart’s performance to support physician’s decisions.
V6 (Foresight Vision 6)
Accommodating Intra Ocular Lens. A flexible IOL structure, using the ciliary muscles activate and control accommodation. The design is based on soft, silicone oil, structure.
Innoventric Tricuspid Regurgitation – TR leads to Increased Venous pressures, impaired liver and kidney function, reduced cardiac output, and, Heart Failure. Ineffective drug treatment for advanced TR, while surgery is hardly performed (1% or TR) and of high mortality risk.
Proprietary DFV technology, based on electronic, software and optic array, allows the extension of the field of view up to 270 degrees without moving the device and without zoom in/out. A tailor made real time video processing embedded software and camera manipulation will position the MaxScope™ at the frontier of the endoscopy field for many years to come.
DarioHealth Corp. is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day in age, knowledge of health and treatment is being democratized and we believe people deserve to know everything about their own health, and at the same time have the best tools to manage their treatment. Dario guides people around the world through their daily challenges with diabetes. Dario changed the way people thrive with diabetes, empowering them with the world’s first slick blood-glucose device that automatically syncs with their smartphone to provide 100% data-capturing, real-time insights and personalized actions. Healthcare companies and wellness providers can leverage our engagement platform and AI technology integrating within any clinical program to support their dynamic, personalized care services and innovations.
Develop and commercializing safe and effective neurovascular medical devices that are beneficial to patients and meet physicians' needs. Rapid are committed to advancing patient
care by providing the most reliable, easiest to use and highest quality products supported by proven clinical data.
Menachem Begin St. 37
Tel: +972 3 565 2285